PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer
Luis Paz-Ares, Benjamin Besse, Michael Thomas, J Aerts et autres
es, fr, de, nl, tw, us, jp, kr, gb (code pays fourni par la source)